This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN
by Zacks Equity Research
Let us take a look at what is in store for some of the drug/biotech stocks, which are scheduled to report on Aug 5.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Incyte (INCY) Q2 Earnings & Sales Beat on Solid Jakafi Growth
by Zacks Equity Research
Incyte (INCY) beats earnings and sales estimates in the second quarter as Jakafi sales register growth.
4 Pharma/Biotech Stocks Poised to Beat on Earnings in Q2
by Ekta Bagri
We take a look at a few pharma/biotech companies, which are poised to beat on earnings in the second quarter.
Incyte (INCY) to Post Q2 Earnings: Will Jakafi Sales Disappoint?
by Zacks Equity Research
Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports second-quarter 2021 results.
Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY
by Zacks Equity Research
Let us take a look at five drug/biotech companies - PFE, GSK, BMY, BMRN and TLRY - which are gearing up for their earnings release.
The Zacks Analyst Blog Highlights: Apple, Danaher, Novartis, AT&T and Estee Lauder
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Danaher, Novartis, AT&T and Estee Lauder
Top Stock Reports for Apple, Danaher & Novartis
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Danaher (DHR), and Novartis (NVS).
Glaxo (GSK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven second-quarter sales. However, sales of vaccines are likely to have been hurt by COVID-19 vaccine prioritization.
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, PFE, ABBV, LLY & MRK FDA Updates
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.
Roche's (RHHBY) 1H21 Sales Rise Despite Impact of Biosimilars
by Zacks Equity Research
Roche's (RHHBY) performance in first-half 2021 was impressive on strong demand for new medicines and COVID-19 test kits. Impact of biosimilars continues to hurt sales.
Merck (MRK) Heart Failure Drug Verquvo Gets Approval in Europe
by Zacks Equity Research
Merck (MRK)/Bayer's (BAYRY) vericiguat gets approval for symptomatic chronic heart failure in patients with reduced ejection fraction in Europe.
Company News for Jul 22, 2021
by Zacks Equity Research
Companies in The News Are: NVS,CMA,IPG,MTB
Novartis' (NVS) Q2 Earnings Top Estimates as Businesses Recovers
by Zacks Equity Research
Novartis (NVS) reports mixed results for the second quarter, as key brands maintain momentum and businesses show signs of recovery.
Why Novartis (NVS) Might Surprise This Earnings Season
by Zacks Equity Research
Novartis (NVS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on commercialization plans for new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports second-quarter earnings.
Will J&J (JNJ) Initiate Pharma Q2 Earnings With a Beat?
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market. Market recovery might have led to continued recovery in Medical Devices segment in the second quarter.
Celldex (CLDX) Up Almost 40% Since Skin Disorder Study Data
by Zacks Equity Research
Celldex (CLDX) announces 95% response rate in urticaria patients in an early-stage study evaluating a single dose of its antibody candidate, CDX-0159. Shares are up almost 40% since last Friday.
Biogen (BIIB) Gets FDA Nod for Narrow Label of Aduhelm
by Zacks Equity Research
The FDA approves label update for Biogen's (BIIB) new Alzheimer's drug, Aduhelm. The updated label narrows the patient population, which is eligible for the drug.
Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on
by Debanjana Dey
Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.
Deciphera (DCPH) Begins Dosing in Study on Cancer Candidate
by Zacks Equity Research
Deciphera (DCPH) doses the first patient in a phase I study evaluating its ULK kinase inhibitor, DCC-3116, for treating advanced/metastatic tumors driven by mutations in RAS/RAF genes.
Gilead's (GILD) Kite Announces Positive Data on Yescarta
by Zacks Equity Research
Gilead (GILD) announces results from the ZUMA-7 study on Yescarta and completes submission of application to the FDA seeking approval of lenacapavir.
Incyte's (INCY) Lymphoma Drug Obtains Positive CHMP Opinion
by Zacks Equity Research
Incyte (INCY) and MorphoSys (MOR) receive positive CHMP opinion for tafasitamab in combination with Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Lilly's (LLY) AD Candidate Gets Breakthrough Therapy Status
by Zacks Equity Research
Eli Lilly (LLY) is developing donanemab in a phase III study and plans to file a regulatory application seeking accelerated approval for the candidate as a treatment for AD in 2021.
Roche's (RHHBY) BLA for PDS With Ranibizumab Accepted by FDA
by Zacks Equity Research
The FDA accepts and grants Priority Review to Roche's (RHHBY) application for Port Delivery System with ranibizumab for the treatment of nAMD.